吃瓜黑料网

Craig joined 吃瓜黑料网 in December 2016. In January 2017 he transitioned to the role of CEO, leading the company鈥檚 efforts to advance organ technology to make every organ count.

Prior to joining the company, Craig served as managing director at Siemens Magnet Technology and simultaneously held a role as an executive member of the Siemens Healthcare MRI business between 2010 and 2016. While at Siemens Magnet Technology, Craig applied his expertise in production and research and development to the development of a revolutionary new magnet contained within the World's strongest clinical MRI system, the Siemens MRI 7 Tesla product, MAGNETOM Terra. In addition, he previously held positions at Oxford Instruments, Amersham Plc and GE Healthcare in a variety of management and leadership roles within the in vivo diagnostics sector.

Craig holds an MBA from the University of Warwick Business School and a Bachelor鈥檚 of Engineering in Medical Engineering from the University of Liverpool.

Peter is 吃瓜黑料网 Co-Founder and Chief Medical Officer, and has worked with Constantin and the 吃瓜黑料网 team for more than 20 years on the development of 吃瓜黑料网's normothermic organ perfusion technology. Peter leads 吃瓜黑料网's pre-clinical and clinical programmes of 吃瓜黑料网's patented normothermic organ perfusion technology.

Peter is Professor of Transplantation at the University of Oxford and Director of the Oxford Transplant Centre, where he is responsible for the kidney, small bowel and pancreatic transplant programmes. Earlier in his career Peter was Clinical Director of the Transplant Centre at Addenbrooke鈥檚 Hospital, Cambridge, one of the UK鈥檚 leading liver transplant centres and visiting Assistant Professor of Surgery at Indiana University Medical Centre, USA, where he established their liver transplant programme.

Peter's research interests lie primarily in novel applications of normothermic organ perfusion, ranging from its use for extracorporeal support to preservation and repair prior to transplantation. He has published over 25 papers on the topic of normothermic perfusion, the basis of the 吃瓜黑料网 technology, as well as in the areas of clinical transplantation, immunosuppression, monoclonal antibodies, xenotransplantation, liver perfusion and aspects of general surgery.

Constantin is 吃瓜黑料网 Co-Founder and Chief Technical Officer and has worked with Peter and the 吃瓜黑料网 team for more than 20 years on the development of 吃瓜黑料网's normothermic organ perfusion technology. Constantin leads 吃瓜黑料网's technical development programmes.

Constantin is Professor of Biomedical Engineering at the University of Oxford and Director of the Oxford Institute of Biomedical Engineering. Constantin founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), he is also the Director of the Oxford Centre for Drug Delivery Devices (OxCD3).

Constantin's research interests include normothermic organ perfusion, drug delivery, acoustic cavitation and therapeutic ultrasound. Constantin received the 2017 Royal Academy of Engineering Silver Medal and was appointed as a Fellow of the Royal Academy of Engineering in 2019.

Rupa Basu joined 吃瓜黑料网 in April 2022 and leads the company in the role of Global Chief Commercial Officer and President, North America.

She brings over 25 years of MedTech experience to the role, having built successful commercial organizations and supported many product launches in her career. Rupa鈥檚 career in US Healthcare began with Bayer Pharmaceuticals where she honed her skills in both clinical and sales roles. She then transitioned to St Jude Medical (now Abbott), progressively taking on leadership positions including leading the Corporate Accounts team and guiding negotiations and implementation of multi-product contracts in GPOs, IDNs, IHNs and multi-hospital systems. Prior to joining 吃瓜黑料网, she led the commercial and strategic business development of cardiac, neuro and vascular therapies at Biotronik in the US managing multiple P&L entities for the company.

Rupa holds an MBA from Ohio University and a BS in Math, Physics and Economics from Punjab University.

Stephen joined 吃瓜黑料网 in April 2024 as Chief Financial Officer. He is responsible for overseeing accounting, financial planning and analysis, and investor relations.

With a distinguished career spanning the healthcare and medical device industries, Stephen brings a wealth of financial leadership to 吃瓜黑料网. His most recent role was as Chief Financial Officer of Paragon 28, Inc., a leading medical device company where he successfully led the company through significant growth, including its IPO and follow on public offering that raised over $220 million.

Prior to Paragon 28, Stephen held senior financial positions at BioScrip, Inc. and Zimmer Biomet. He also has several years of Big Four public accounting experience. His financial acumen and strategic thinking have been instrumental in driving business success and maximizing shareholder value.

Stephen holds a B.S. in Accounting from Ball State University and has an in-active CPA license. He is also a seasoned board member, currently serving on the boards of Aclarion, Inc. and Auddia Inc.

David joined 吃瓜黑料网 in July 2024 as Chief HR Officer, bringing a wealth of experience in HR leadership roles within purpose-led organizations, primarily in the life sciences and technology sectors.

Prior to joining 吃瓜黑料网, David held the position of CHRO at Novacyt, a publicly listed clinical diagnostics company. He spent nine years at Gilead Sciences in several HR leadership roles. Additionally, David has held both specialist and generalist HR roles at organizations such as Amey, Vodafone, EY, and HayGroup (now Korn Ferry). David鈥檚 early career was as an organisational psychologist in the Employment service.

In addition to his executive roles, David has served as a Trustee, as a Board Observer, and has been a mentor for a number of early-stage companies. David holds a BA (Hons) in Psychology and a Diploma in Applied Psychology from the University of Nottingham.

Graham joined 吃瓜黑料网 in June 2019, bringing with him extensive experience in leading senior teams within high-growth SMEs. He has a proven track record in implementing financial controls, managing significant change and growth, building operational capability, and driving profitability and cash generation.

Graham's career in life sciences began in 2006, and since then, he has been involved in two IPOs, numerous fundraisings, and complex licensing transactions. His previous roles include Chief Financial Officer at Neuropharm Group plc and then hVIVO plc, where he played a pivotal role in the growth and financial success of both companies. Prior to his career in life sciences, Graham spent 13 years at PricewaterhouseCoopers, gaining valuable experience in audit, tax, consultancy, business process re-engineering, and outsourcing. He also served as Finance & Operations Director at Proxima, where he helped establish the company as a leading UK purchasing services provider.

Graham holds a first-class BSc in Economics and Maths from the University of Bristol.